Stockscreener 앱 받기
7.13
7.22%
0.48
시간 외 거래:
7.17
0.04
+0.56%
전일 마감가:
$6.65
열려 있는:
$6.51
하루 거래량:
743.05K
Relative Volume:
0.99
시가총액:
$322.00M
수익:
$123.87M
순이익/손실:
$62.49M
주가수익비율:
4.2707
EPS:
1.6695
순현금흐름:
$-87.53M
1주 성능:
+11.41%
1개월 성능:
-24.39%
6개월 성능:
+83.29%
1년 성능:
+76.49%
1일 변동 폭
$6.47
$7.14
1주일 범위
$6.11
$7.14
52주 변동 폭
$2.71
$10.31
아제너스 Stock (AGEN) Company Profile
명칭
Agenus Inc
전화
781-674-4410
주소
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
7.13 | 322.00M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
529.69 | 134.26B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
214.16 | 85.50B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
813.27 | 83.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.76 | 56.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
373.36 | 42.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
아제너스 Stock (AGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-28 | 개시 | Rodman & Renshaw | Buy |
| 2026-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2026-07-13 | 재확인 | H.C. Wainwright | Buy |
| 2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | 개시 | Robert W. Baird | Outperform |
| 2023-02-28 | 재개 | H.C. Wainwright | Buy |
| 2022-09-28 | 개시 | SMBC Nikko | Outperform |
| 2021-12-16 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 재개 | B. Riley FBR | Buy |
| 2019-04-22 | 개시 | B. Riley FBR | Buy |
| 2016-10-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | 재확인 | Maxim Group | Buy |
| 2016-03-11 | 업그레이드 | Maxim Group | Hold → Buy |
| 2015-12-16 | 개시 | Jefferies | Buy |
| 2015-10-27 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2015-07-27 | 재확인 | MLV & Co | Buy |
| 2015-06-11 | 개시 | Oppenheimer | Outperform |
| 2015-01-12 | 재확인 | Maxim Group | Buy |
| 2015-01-09 | 재확인 | MLV & Co | Buy |
| 2015-01-09 | 재확인 | Maxim Group | Buy |
| 2014-12-19 | 재확인 | Maxim Group | Buy |
| 2014-05-08 | 재확인 | Maxim Group | Buy |
| 2014-03-14 | 재확인 | MLV & Co | Buy |
| 2013-10-08 | 재확인 | Maxim Group | Buy |
| 2012-01-05 | 개시 | William Blair | Outperform |
| 2011-12-01 | 개시 | Global Hunter Securities | Buy |
모두보기
아제너스 주식(AGEN)의 최신 뉴스
Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight - GlobeNewswire Inc.
A Defining Moment for Cancer Immunotherapy During ESMO 2026 – Agenus - Oncodaily
Agenus at Chardan’s 10th annual healthcare conference: pivot to ROBIN - Investing.com
Form 4 Agenus Inc: Timothy Wright (Director) For: 1 October By Investing.com - Investing.com India
Form 4 Agenus Inc: Timothy Wright (Director) For: 1 October By Investing.com - Investing.com Canada
Form 4 Agenus Inc: Thomas L. Harrison (Director) For: 1 October - Investing.com Nigeria
Form 4 Agenus Inc: Thomas L. Harrison (Director) For: 1 October - Investing.com UK
Agenus to Participate in Upcoming September Investor Conferences - The National Law Review
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference - BioSpace
Agenus Inc. (AGEN) options chain - Yahoo Finance UK
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance Singapore
Agenus Inc. (AGEN) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference - Business Wire
Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination - Yahoo Finance
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer - Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - 뉴스와이어
Agenus (AGEN) Reports Durable 3-Year Ovarian Cancer Trial Results Amid Valuation and Financial Challenges - GuruFocus
Agenus Inc. (AGEN) latest stock news and headlines - Yahoo Finance UK
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Yahoo Finance
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 - BioSpace
Director Wright acquires 1.18K units of future Agenus (AGEN) shares at $6.893 each. - Stock Titan
A director acquires 4,443 Agenus (AGEN) shares through an election to receive fees in stock. - Stock Titan
Joe Cotton’s Stock Pick of the Week: A risky biotech stock, Agenus, a promising colorectal cancer drug - NKyTribune
Agenus Inc. Initiates Landmark Phase 3 BATTMAN Trial In MSS Metastatic Colorectal Cancer - BioPharma APAC
Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock SoaringBut Caution Advised - Seeking Alpha
Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN) - Seeking Alpha
Agenus Shares Rise After Chardan Initiates Coverage at Buy - marketscreener.com
AGEN Initiates Coverage On Agenus by Rodman & Renshaw -- Rating Buy - GuruFocus
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy - Investing.com Nigeria
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy - Investing.com
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - easternprogress.com
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Dura - The National Law Review
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Dura - The National Law Review
Agenus Stock Price Forecast. Should You Buy AGEN? - StockInvest.us
New Agenus (AGEN) director receives 7,500 stock options - Stock Titan
Spouse-held shares feature in Agenus (AGEN) director's stake - Stock Titan
September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant ImmunotherapyAgenus - Oncodaily
Agenus Inc Share PriceAGEN, RNS News, Articles, Quotes, & Charts (NASDAQ:AGEN) - Proactive financial news
AGEN S-3 FilingsAgenus Inc. SEC S-3 - stocktitan.net
Agenus Inc. (AGEN) Shareholder/Analyst CallSlideshow (NASDAQ:AGEN) 2026-09-11 - Seeking Alpha
BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - BioSpace
Agenus to Present 3-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - New Castle News
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Business Wire
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Yahoo Finance
Agenus Company Profile & Introduction - moomoo.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Agenus to Participate in Upcoming September Investor Conferences - Business Wire
Agenus to Participate in Upcoming September Investor Conferences - Yahoo Finance
아제너스 (AGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
44.16%
6.39%
자본화:
|
볼륨(24시간):